Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed non-small cell lung cancer

- Stage IB (T2, N0), II (T1 or T2, N1 or T3, N0), or IIIA (T3, N1)

- Potentially resectable disease

- No large central primary tumors in proximity to significant blood vessels

- No bronchoscopically evident endobronchial tumors

- At least 1 unidimensionally measurable lesion

- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

- No known brain metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-1 OR

- Karnofsky 70-100%

Life expectancy:

- More than 12 months

Hematopoietic:

- WBC at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- No history of an inherited bleeding disorder

- No inherited predisposition to a hypercoagulable state

- No clinically evident hypercoagulable state or bleeding diathesis

Hepatic:

- Bilirubin less than 1.5 times upper limit of normal (ULN)

- AST/ALT no greater than 2.5 times ULN

- INR less than 1.5

- PTT less than 36 seconds

Renal:

- Creatinine less than 1.5 times ULN OR

- Creatinine clearance at least 60 mL/min

- No nephrotic syndrome

- Urine protein no greater than 0.5 g/24 hours

Cardiovascular:

- No poorly controlled hypertension (greater than 150 mm Hg systolic and/or greater
than 100 mm Hg diastolic) despite treatment

- No uncompensated coronary artery disease

- No myocardial infarction within the past 6 months

- No clinically significant or severe peripheral vascular disease

- No inherited predisposition to thrombosis

- No deep venous or arterial thrombosis

- No symptomatic congestive heart failure

- No unstable angina pectoris within the past 6 months

- No cardiac arrhythmia

- No transient ischemic attack within the past 6 months

- No cerebrovascular accident within the past 6 months

- No other arterial thromboembolic event within the past 6 months

Pulmonary:

- No hemoptysis

- No pulmonary embolism

Other:

- No history of allergic reactions to compounds of similar chemical or biologic
composition to study drugs

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human or humanized antibodies

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No psychiatric illness or social situation that would preclude study compliance

- No significant traumatic injury within the past 28 days

- No uncontrolled concurrent illness

- No ongoing or active infection

- No serious, non-healing wound, ulcer, or bone fracture

- No other active malignancy

- No requirement for full-dose anticoagulation or thrombolytic therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior biologic therapy for this cancer

- No concurrent prophylactic growth factors (e.g., epoetin alfa, filgrastim [G-CSF], or
sargramostim [GM-CSF])

Chemotherapy:

- No prior chemotherapy for this cancer

- Prior chemotherapy for another malignancy allowed provided the prior malignancy was
curatively treated and is currently controlled

Endocrine therapy:

- No prior endocrine therapy for this cancer

Radiotherapy:

- No prior radiotherapy for this cancer

- Prior radiotherapy for another malignancy allowed provided the prior malignancy was
curatively treated and is currently controlled

- No concurrent radiotherapy

Surgery:

- Prior diagnostic bronchoscopy, mediastinoscopy, or CT-guided biopsy allowed

- At least 28 days since prior major surgical procedure or open biopsy

Other:

- No other concurrent investigational agents

- No other concurrent anticancer investigational or commercial agents or therapies

- No concurrent combination antiretroviral therapy for HIV-positive patients

- Concurrent low-dose warfarin for maintenence of preexisting, permanent, indwelling IV
catheters allowed provided INR less than 1.5